Earnings Call Excerpt
Monogram Biosciences, Inc. (MGRM)
Q4 2007 Earnings Call
February 7, 2008 4:30 pm ET
Executives
Alfred Merriweather – CFO
Bill Young – CEO
Christos Petropoulos Ph.D. – Chief Scientific Officer
Bill Welch – Chief Commercial Officer and Sr. VP
Analysts
Zarak Khurshid – Caris & Company
William Quirk – Piper Jaffray
Peter Lawson – Peter Weisel Partners
Keay Nakkae – Collins Stewart LLC
Jeffrey Frelick – Lizard Capital Markets
Matthew Scalo – Canaccord Adams
Mike Chu - Civic
Presentation
Operator
Good day and welcome everyone to the Monogram Biosciences Fourth Quarter 2007 Financial Results Conference Call.
At this time I would like to turn the conference over to Mr. Alfred G. Merriweather, Senior Vice President and Chief Financial Officer. Please go ahead sir.
Alfred Merriweather
Thank you for joining us today.
The copy of the press release highlighting the information to be discussed in this call can be found on the Investor Relation section of our website. Before we begin, I would like to point out that some of our comments today will be forward-looking including those regard in the following: anticipated revenue, operation result, cash flow, and activities for 2008, prospects for Pfizer CCR5 antagonist Selzentry, potential use of our Trofile assay along with Selzentry, while our third party payers will establish reimbursement for Trofile and the amount of such reimbursement.
Implementation of the Pfizer collaboration with the FDA or any other agency will further regulate our current or future products, the timing and results of on going and planned clinical studies related to the effectiveness of our VeraTag assays, anticipated timing and success with the validation and commercial launch per mark and other potential products based on our VeraTag technology, and the protection afforded by intellectual property.
These forward-looking statements are subject to risks, uncertainties and other factors which may cause actual results to differ materially from anticipated results or expectations. For a discussion of these factors, please refer to today's press release and our SEC filings. The Company does not undertake and specifically disclaims any obligation to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.
I would now like to turn the call over to Bill Young Young, Chairman and CEO of Monogram.
Bill Young
Thanks, Alf, and good afternoon everyone. Our Quarter Four financial results reported today indicate that 2007 has as we have been predicting than it has been a pivotal year. Over the course of this call, we will review the operational highlights and progress for Trofile. Our land mark HIV Tropism Assay and for HERmark the first product based on our VeraTag technology platform.
- To read the full transcript on Seeking Alpha, click here »
